Literature DB >> 16341027

Sustained reductions in neonatal nosocomial infection rates following a comprehensive infection control intervention.

R L Schelonka1, S Scruggs, K Nichols, R A Dimmitt, W A Carlo.   

Abstract

OBJECTIVE: Nosocomial infections (NI) are a frequent and important cause of morbidity and mortality in newborn infants who receive intensive care. We sought to determine if comprehensive infection control (CIC) measures decrease rates in a large neonatal intensive care nursery.
METHODS: Single center interventional study. The CIC intervention consisted of increasing nursing and physician education and awareness of infection rates, establishing common improvement goals, training in hand and environment care, and implementing a specialty nursing team for central venous and arterial catheter care. Demographic and microbiology information for all infants admitted to the NICU from January 1, 1999 to December 31, 2000 established baseline data. The intervention period was during January and February 2001. The postintervention period was March 1, 2001 to February 29, 2004. The main outcome measure was the rate of blood, cerebrospinal and/or urinary tract bacterial infections per 1000 hospital days.
RESULTS: Baseline infection rate was 8.5 per 1000 hospital days. The NI rate fell 26% (P=0.002) from baseline in the first year and 29% (P<0.001) in the second and third years after the CIC intervention. The reduction in total NI was due mostly to a 46% fall in coagulase-negative Staphylococcus infection rate (P<0.001); however, rates of all other organisms also fell by 21% (P=0.05).
CONCLUSIONS: CIC measures can reduce bacterial and fungal NI rates. This effect has been sustained for 3 years following the intervention.

Entities:  

Mesh:

Year:  2006        PMID: 16341027     DOI: 10.1038/sj.jp.7211411

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  7 in total

Review 1.  Understanding the significance of Staphylococcus epidermidis bacteremia in babies and children.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Curr Opin Infect Dis       Date:  2010-06       Impact factor: 4.915

Review 2.  Challenges and opportunities for antibiotic stewardship among preterm infants.

Authors:  Sagori Mukhopadhyay; Shaon Sengupta; Karen M Puopolo
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2018-11-13       Impact factor: 5.747

3.  Nosocomial infection reduction in VLBW infants with a statewide quality-improvement model.

Authors:  David D Wirtschafter; Richard J Powers; Janet S Pettit; Henry C Lee; W John Boscardin; Mohammad Ahmad Subeh; Jeffrey B Gould
Journal:  Pediatrics       Date:  2011-02-21       Impact factor: 7.124

4.  Late-onset Sepsis in Extremely Premature Infants: 2000-2011.

Authors:  Rachel G Greenberg; Sarah Kandefer; Barbara T Do; P Brian Smith; Barbara J Stoll; Edward F Bell; Waldemar A Carlo; Abbot R Laptook; Pablo J Sánchez; Seetha Shankaran; Krisa P Van Meurs; M Bethany Ball; Ellen C Hale; Nancy S Newman; Abhik Das; Rosemary D Higgins; C Michael Cotten
Journal:  Pediatr Infect Dis J       Date:  2017-08       Impact factor: 3.806

5.  Nosocomial infection in small for gestational age newborns with birth weight <1500 g: a multicentre analysis.

Authors:  Dorothee B Bartels; Frank Schwab; Christine Geffers; Christian F Poets; Petra Gastmeier
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-04-25       Impact factor: 5.747

Review 6.  Antimicrobial-impregnated central venous catheters for prevention of catheter-related bloodstream infection in newborn infants.

Authors:  Munisha Balain; Sam J Oddie; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2015-09-27

7.  Sustained Reduction in Bloodstream Infections in Infants at a Large Tertiary Care Neonatal Intensive Care Unit.

Authors:  Sara Neill; Sarah Haithcock; P Brian Smith; Ronald Goldberg; Margarita Bidegain; David Tanaka; Charlene Carriker; Jessica E Ericson
Journal:  Adv Neonatal Care       Date:  2016-02       Impact factor: 1.874

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.